Original Article

Surging Liver Transplantation for Nonalcoholic Steatohepatitis from 2000–2022: A National Database Study

Authors: Tokunbo Ajayi, MD, Gina Moon, MD, Sixia Chen, PhD, Steven Pan, MS, Abdul Oseini, MD, Courtney Houchen, MD

Abstract

Objectives: Our aim was to provide an up-to-date, large-scale overview of the trends and clinicodemographics for NASH LTs performed in the United States compared with all other LT indications between 2000 and 2022. We also examined the demographic factors that will predict future demand for NASH LT.

Methods: Our analysis of NASH LT from the Organ Procurement & Transplantation Network database spanning 2000–2022 consisted primarily of descriptive statistics and hypothesis testing with corrections for multiple testing when necessary. Trend lines and linear correlations were also explored.

Results: NASH LTs have experienced a remarkable surge, escalating from 0.12% of all LTs in 2000 to a substantial 14.7% in 2022, marking a 100-fold increase. Examining demographic trends, a significant proportion of NASH LTs recipients fall within the 50- to 64-year-old age group. Moreover, 52% of these recipients concurrently exhibit type 2 diabetes mellitus, a notably higher percentage than the 19% observed in all LT recipients. Type 2 diabetes mellitus emerges as a prominent risk factor for NASH progressing to end-stage liver disease. The phenomenon of repeat transplantation is noteworthy; although 6% of all LTs necessitate repeat procedures, this figure dramatically drops to 0.6% for NASH LTs. Ethnic disparities are apparent, with African Americans representing a mere 2% of NASH LT recipients, significantly lower than their representation in the overall population. Regionally, the East Coast has a higher proportion of NASH LT recipients compared with waitlist additions. This trend holds true across demographics.

Conclusions: Our findings underscore the need for increased resources, particularly for minority, uninsured, or noncitizen individuals requiring LT for NASH. This analysis provides valuable insights into the dynamic landscape of LTs in the context of NASH, shaping the trajectory of medical interventions in the 21st century.
Posted in: Liver Disease7

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Perumpail BJ, KhanMA, Yoo ER, et al. Clinical epidemiology and disease burden of nonalcoholic fatty liver disease. World J Gastroenterol 2017;23:8263–8276.
 
2. Kneeman JM, Misdraji J, Corey KE. Secondary causes of nonalcoholic fatty liver disease. Therap Adv Gastroenterol 2012;5:199–207.
 
3. Powell EE, Wong VWS, Rinella M. Non-alcoholic fatty liver disease. Lancet 2021;397:2212–2224.
 
4. Allen AM, Therneau TM, Larson JJ, et al. Nonalcoholic fatty liver disease incidence and impact on metabolic burden and death: a 20 year-community study. Hepatology 2018;67:1726–173.
 
5. Estes C, Anstee QM, Arias-Loste MT, et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. J Hepatol 2018;69:896–904.
 
6. Kumar R, Priyadarshi RN, Anand U. Non-alcoholic fatty liver disease: growing burden, adverse outcomes and associations. J Clin Transl Hepatol 2020;8:76–86.
 
7. Schuppan D, Surabattula R, Wang XY. Determinants of fibrosis progression and regression in NASH. J Hepatol 2018;68:238–250.
 
8. Organ Procurement and Transplantation Network. Build advanced. https://optn.transplant.hrsa.gov/data/view-data-reports/build-advanced. Accessed March 30, 2024.
 
9. Noureddin M, Vipani A, Bresee C, et al. NASH leading cause of liver transplant in women: updated analysis of indications for liver transplant and ethnic and gender variances. Am J Gastroenterol 2018;113:1649–1659.
 
10. Sheka AC, Adeyi O, Thompson J, et al. Nonalcoholic steatohepatitis: a review. JAMA 2020;323:1175–1183.
 
11. Centers for Disease Control and Prevention. National diabetes statistics report. https://www.cdc.gov/diabetes/data/statistics-report/index.html. Published February 5, 2022. Accessed March 30, 2024.
 
12. Shingina A, DeWitt PE, Dodge JL, et al. Future trends in demand for liver transplant: birth cohort effects among patients with NASH and HCC. Transplantation 2019;103:140–148.
 
13. Stepanova M, Kabbara K, Mohess D, et al. Nonalcoholic steatohepatitis is the most common indication for liver transplantation among the elderly: data from the United States Scientific Registry of Transplant Recipients. Hepatol Commun 2022;6:1506–1515.
 
14. Loy VM, Joyce C, Bello S, et al. Gender disparities in liver transplant candidates with nonalcoholic steatohepatitis. Clin Transplant 2018;32:e13297.
 
15. Rodriguez LM, Litt DM, Stewart SH. Drinking to cope with the pandemic: the unique associations of COVID-19-related perceived threat and psychological distress to drinking behaviors in American men and women. Addict Behav 2020;110:106532.
 
16. Hajifathalian K, Humberson A, Hanouneh MA, et al. Ohio solid organ transplantation consortium criteria for liver transplantation in patients with alcoholic liver disease. World J Hepatol 2016;8:1149–1154.
 
17. Hirode G, Wong RJ. Trends in the prevalence of metabolic syndrome in the United States, 2011-2016. JAMA 2020;323:2526–2528.
 
18. Payne JY, Alkhouri N, Le P, et al. Prevalence of at-risk NASH and its association with metabolic syndrome in US adults with NAFLD, 2017-2018. Hepatol Commun 2023;7:e0019.
 
19. Caldwell SH, Harris DM, Patrie JT, et al. Is NASH underdiagnosed among African Americans? Am J Gastroenterol 2002;97:1496–1500.
 
20. Oseini AM, Sanyal AJ. Therapies in non-alcoholic steatohepatitis (NASH). Liver Int 2017;37:97–103.
 
21. Ahmed O, Liu L, Gayed A, et al. The changing face of hepatocellular carcinoma: forecasting prevalence of nonalcoholic steatohepatitis and hepatitis C cirrhosis. J Clin Exp Hepatol 2019;9:50–55.
 
22. Feld JJ, Jacobson IM, Hézode C, et al. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med 2015;373:2599–2607.
 
23. Foster GR, Afdhal N, Roberts SK, et al. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N Engl J Med 2015;373:2608–2617.
 
24. Cullaro G, Sarkar M, Lai JC. Sex-based disparities in delisting for being “too sick” for liver transplantation. Am J Transplant 2018;18:1214–1219.
 
25. Rich NE, Oji S, Mufti AR, et al. Racial and ethnic disparities in nonalcoholic fatty liver disease prevalence, severity, and outcomes in the United States: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2018;16: 198–210.e2.
 
26. Bril F, Portillo-Sanchez P, Liu IC, et al. Clinical and histologic characterization of nonalcoholic steatohepatitis in African American patients. Diabetes Care 2018;41:187–192.
 
27. Sun C, Kovacs P, Guiu-Jurado E. Genetics of body fat distribution: comparative analyses in populations with European, Asian and African ancestries. Genes 2021;12:841.
 
28. Martos-Moreno GÁ, Martínez-Villanueva J, González-Leal R, et al. Ethnicity strongly influences body fat distribution determining serum adipokine profile and metabolic derangement in childhood obesity. Front Pediatr 2020;8:551103.
 
29. Guerrero R, Vega GL, Grundy SM, et al. Ethnic differences in hepatic steatosis: an insulin resistance paradox? Hepatology 2009;49:791–801.
 
30. Romeo S, Kozlitina J, Xing C, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2008;40: 1461–1465.
 
31. Muzica CM, Sfarti C, Trifan A, et al. Nonalcoholic fatty liver disease and type 2 diabetes mellitus: a bidirectional relationship. Can J Gastroenterol Hepatol 2020;2020:6638306.
 
32. Department of Health and Human Services, Administration for Community Living. A profile of older Americans. https://acl.gov/aging-and-disability-in-america/data-and-research/profile-older-americans. Accessed March 30, 2024.
 
33. Charlton MR, Burns JM, Pedersen RA, et al. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology 2011;141:1249–1253.